Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. BioVaxys Technology Corp.
  6. Summary
    BIOV   CA09076M1014

BIOVAXYS TECHNOLOGY CORP.

(BIOV)
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Canadian National Stock E…
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
0.265(c) 0.245(c) 0.245(c) 0.27(c) 0.315(c) Last
329 558 105 300 216 498 64 913 451 958 Volume
+6.00% -7.55% 0.00% +10.20% +16.67% Change
More quotes
Estimated financial data (e)
Sales 2019 - - -
Net income 2019 -0,23 M -0,18 M -0,18 M
Net cash position 2019 0,23 M 0,18 M 0,18 M
P/E ratio 2019 -
Yield 2019 -
Sales 2020 - - -
Net income 2020 -1,17 M -0,92 M -0,92 M
Net cash position 2020 2,42 M 1,89 M 1,89 M
P/E ratio 2020 -10,1x
Yield 2020 -
Capitalization 29,0 M 22,7 M 22,7 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees -
Free-Float 57,7%
More Financials
Company
BioVaxys Technology Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is using its haptenized antigen technology platforms to develop vaccines to treat viral infections, such as SARS-CoV-2, human papillomavirus (HPV) and cancers, such as late-stage ovarian cancer, cervical cancer and... 
Sector
Biotechnology & Medical Research
Calendar
12/01 | 08:10pmPresentation
More about the company
All news about BIOVAXYS TECHNOLOGY CORP.
11/18BioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeuti..
AQ
11/09BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging I..
AQ
11/09Biovaxys Technology Corp. Announces that CoviCoviDTH Demonstrates Safety and Tolerabili..
CI
10/28BioVaxys Further Expands Intellectual Property Portfolio in Global Markets
AQ
10/28BioVaxys Technology Corp. Files Applications for International Patent and Trademark Pro..
CI
10/20BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
CI
10/20BIOVAXYS TECHNOLOGY : Files US Patent Application for Pan-Sarbecovirus Vaccine
AQ
10/08BIOVAXYS TECHNOLOGY : Announces BVX-0320 Poster Presentation at ISIRV-WHO Virtual Conferen..
AQ
09/29Biovaxys Technology Corp. Reports Earnings Results for the Third Quarter Ended July 31,..
CI
09/28BIOVAXYS TECHNOLOGY : Begins Toxicity Study Ahead of CoviDTH IND Submission
AQ
09/28BioVaxys Technology Corp. Begins Toxicity Study Ahead of CoviDTH IND Submission
CI
09/23BIOVAXYS TECHNOLOGY : Prepares for Groundbreaking Study on reduced ACE2 binding capabiliti..
AQ
09/23BioVaxys Prepares for Study on Reduced ACE2 Binding Capabilities of Hapten-Modified SAR..
CI
09/17BIOVAXYS TECHNOLOGY : Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproductio..
AQ
09/17BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Mileston..
CI
More news
News in other languages on BIOVAXYS TECHNOLOGY CORP.
09/23BIOVAXYS TECHNOLOGY CORP. : Biovaxys bereitet sich auf eine bahnbrechende Studie zur reduz..
09/17BIOVAXYS TECHNOLOGY CORP. : Krebsimpfstoff-Herstellungspartner von BioVaxys, Bio Elpida, e..
09/14BIOVAXYS TECHNOLOGY CORP. : Biovaxys: Die Partnerfirma Wuxi Biologics, ein Hersteller von ..
2020IRW-NEWS : BioVaxys Technology Corp.: Biovaxys berichtet über Ergebnisse aus einer In-vivo..
2020IRW-NEWS : Lions Bay Mining Corp.: Update zu Lions Bay Mining: Übernahmeziel BioVaxys künd..
More news
Chart BIOVAXYS TECHNOLOGY CORP.
Duration : Period :
BioVaxys Technology Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
James Christopher Passin Chief Executive Officer & Director
Kenneth E. Kovan President & Chief Operating Officer
Lachlan McLeod Chief Financial Officer & Secretary
David Berd Chief Medical Officer
David Wang Director
Sector and Competitors
1st jan.Capi. (M$)
BIOVAXYS TECHNOLOGY CORP.65.79%23
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678